Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Fei, Bojian ^a   Chi, Alfred L ^b   Weng, Yuan ^a  

^a Department of Surgical Oncology   (China)

^b CHI Scientific Inc   (United States)

Author keywords

10 Hydroxycamptothecin; 5 fluorouracil; Chemotherapy; Colon cancer

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CASPASE 3; CYTOCHROME C; FLUOROURACIL; SMALL INTERFERING RNA; SURVIVIN; SURVIVIN 2B; SURVIVIN 3B; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84878240780     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-120     Document Type: Article

References (35)

1. Yang VW, Lewis J, Wang TC, Rustgi AK. Colon cancer: an update and future directions. Gastroenterology 2010, 138:2027-2028. 10.1053/j.gastro.2010.03.007, 20226784.
2. Aghili M, Izadi S, Madani H, Mortazavi H. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol 2010, 6:35-41. 10.1111/j.1743-7563.2010.01275.x, 20398036.
3. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 1971, 46:789-795.
4. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994, 54:539-546.
5. Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002, 33:1114-1119. 10.1053/hupa.2002.129202, 12454816.
6. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 2012, 19:3874-3885. 10.2174/092986712802002590, 22788763.
7. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012, 106:18-24. 10.1038/bjc.2011.498, 3251848, 22108516.
8. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochim Biophys Acta 1972, 269:210-216. 10.1016/0005-2787(72)90429-7, 5063907.
9. Ling YH, Tseng MT, Nelson JA. Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase I inhibitor. Differentiation 1991, 46:135-141. 10.1111/j.1432-0436.1991.tb00873.x, 1648523.
10. Ling YH, Andersson BS, Nelson JA. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells. Cancer Biochem Biophys 1990, 11:23-30.
11. Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002, 62:2039-2057. 10.2165/00003495-200262140-00004, 12269849.
12. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002, 8:641-661.
13. Chen X, Ran ZH, Tong JL, Nie F, Zhu MM, Xu XT, Xiao SD. RNA interference (RNAi) of Ufd1 protein can sensitize a hydroxycamptothecin-resistant colon cancer cell line SW1116/HCPT to hydroxycamptothecin. J Dig Dis 2011, 12:110-116. 10.1111/j.1751-2980.2011.00478.x, 21401896.
14. Wu XM, Shao XQ, Meng XX, Zhang XN, Zhu L, Liu SX, Lin J, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011, 32:259-269. 10.1038/aps.2010.204, 21293479.
15. Ping YH, Lee HC, Lee JY, Wu PH, Ho LK, Chi CW, Lu MF, Wang JJ. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep 2006, 15:1273-1279.
16. Ling YH, Xu B. Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells. Zhongguo Yao Li Xue Bao 1993, 14:546-550.
17. Zhang XW, Jiang JF, Xu B. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin 2000, 21:364-368.
18. Zhang ZW, Patchett SE, Farthing MJ. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 2000, 11:757-764.
19. Zhang G, Ding L, Renegar R, Wang X, Lu Q, Huo S, Chen YH. Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions. Cancer Sci 2011, 102:1216-1222. 10.1111/j.1349-7006.2011.01930.x, 3098924, 21435100.
20. Hu W, Zhang C, Fang Y, Lou C. Anticancer properties of 10-hydroxycamptothecin in a murine melanoma pulmonary metastasis model in vitro and in vivo. Toxicol In Vitro 2011, 25:513-520. 10.1016/j.tiv.2010.11.009, 21093576.
21. Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC, Tang LN, Zhang W. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. Chin Med J (Engl) 2006, 119:1829-1833.
22. Sinha VR, Honey G. Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer. Crit Rev Ther Drug Carrier Syst 2012, 29:89-148. 10.1615/CritRevTherDrugCarrierSyst.v29.i2.10, 22577701.
23. Medema JP, Scaffidi C, Krammer PH, Peter ME. Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem 1998, 273:3388-3393. 10.1074/jbc.273.6.3388, 9452459.
24. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
25. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998, 273:33942-33948. 10.1074/jbc.273.51.33942, 9852046.
26. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000, 6:513-519. 10.1038/74994, 10802706.
27. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005, 4:139-163. 10.4161/cbt.4.2.1508, 15725726.
28. Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Nakano H, Asakura T, Ohtsubo T, Kobayashi S. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 2007, 30:1400-1406. 10.1248/bpb.30.1400, 17666793.
29. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003, 100:15095-15100. 10.1073/pnas.2435285100, 299914, 14645705.
30. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011, 11:291-316. 10.2174/156802611794072623, 21320059.
31. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11:109-124. 10.1038/nrd3627, 22293567.
32. Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005, 128:361-375. 10.1053/j.gastro.2004.11.058, 15685548.
33. Ge QX, Li YY, Nie YQ, Zuo WG, Du YL. Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med Oncol 2013, 30:535.
34. Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2004, 23:7545-7551. 10.1038/sj.onc.1208038, 15334064.
35. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008, 26:1443-1451. 10.1200/JCO.2007.14.0509, 18349394.